Silence Therapeutics

@SilenceTheraPlc

We are a leader in the development & delivery of RNA therapeutics for the modulation of gene expression up as well as down. Publicly Listed, AIM:SLN.

London
Vrijeme pridruživanja: listopad 2011.

Tweetovi

Blokirali ste korisnika/cu @SilenceTheraPlc

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @SilenceTheraPlc

  1. proslijedio/la je Tweet
    28. stu 2019.

    Silence Therapeutics CEO talks recent RNAi deals and updates on critical SLN124 trial via

    Poništi
  2. proslijedio/la je Tweet
    28. lis 2019.

    Chief executive, David Solomon, updates on across three key - SLN 500, 124 and 360. Discussing the firm's current valuation, Solomon says ''there's a lot more steam in the engine'' Full interview here -

    Poništi
  3. Silence Therapeutics, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces its unaudited interim results for the half year to 30 June 2019.

    Poništi
  4. proslijedio/la je Tweet
    18. srp 2019.

    Mallinckrodt, Silence Therapeutics partner to develop RNAi therapies for complement-mediated diseases

    Poništi
  5. proslijedio/la je Tweet
    19. srp 2019.

    Interview: Mallinckrodt Deal Golden For Silence Therapeutics

    Poništi
  6. David Solomon, CEO of Silence Therapeutics, discussing the transformational deal with Mallinckrodt at Proactive Investors. Watch the full video here

    Poništi
  7. David Solomon commenting of the collaboration with

    Poništi
  8. Very pleased to announce the collaboration between Silence Therapeutics and to fight the unmet needs of rare diseases as well as conditions of immune dysregulations. Watch our CEO, David Solomon speak about this collaboration here

    Poništi
  9. We are delighted to announce that Silence Therapeutics is collaborating with to allow the companies to develop and commercialize RNAi drug targets designed to inhibit the complement cascade. Read more about the collaboration in our press release

    Poništi
  10. Silence Therapeutics is pleased to announce the appointment of Giles Campion, MD as Head of R&D and Chief Medical Officer, effective 1 June 2019.

    Poništi
  11. Silence Therapeutics, PLC announces that a CTA for the Company’s lead candidate SLN124 has been submitted to the UK MHRA.

    Poništi
  12. Silence Therapeutics, PLC announces its unaudited preliminary results for the year ended 31 December 2018.

    Poništi
  13. Silence Therapeutics announces that its lead medicine candidate SLN124 has been granted Orphan Drug Designation by the EMA for the treatment of β-Thalassemia.

    Poništi
  14. Silence Therapeutics announces the addition of a new siRNA (short interfering RNA) asset to its pre-clinical pipeline for the potential treatment of cardiovascular disease.

    Poništi
  15. Silence Therapeutics to attend Haemochromatosis UK reception at The House of Commons, Westminster on Wednesday, October 31, 2018 at 4pm.

    Poništi
  16. Silence Therapeutics plc today reports on the favourable outcome of a decision by the US PTAB against Alnylam.

    Poništi
  17. Silence Therapeutics Announces Receipt of a New European Notice of Intention to Grant a Patent and the Launch of an Interim European Injunction Application against Onpattro™

    Poništi
  18. Silence Therapeutics plc announces that David Horn Solomon, Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Wednesday, October 3, 2018 at 12:15pm EDT in New York, NY.

    Poništi
  19. proslijedio/la je Tweet
    11. ruj 2018.

    Silence Therapeutics to kick off first in-human clinical trial next year via

    Poništi
  20. Silence Therapeutics plc, AIM:SLN a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases, announces its unaudited interim results for the half year to 30 June 2018.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·